Doravirine/Lamivudine/Tenofovir

DRUG2 trials

Sponsors

Thomas Jefferson University, Professor Francois Venter

Conditions

Gender DysphoriaHIV-1-infectionHuman Immunodeficiency VirusTransgender HealthTransgender Women

Phase 1

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

CompletedNCT04283656

Thomas Jefferson UniversityGender Dysphoria, Human Immunodeficiency Virus, Transgender Health +1

Start: 2022-01-04End: 2022-12-30Updated: 2025-03-26

Phase 3

ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance

Professor Francois VenterHIV-1-infection

Start: 2021-02-09End: 2023-09-30Target: 25Updated: 2022-06-07